Abstract | OBJECTIVE: METHODS: We performed an exploratory analysis of participants with diabetic macular edema randomly assigned to receive laser therapy or intravitreal triamcinolone acetonide (1 or 4 mg). Fundus photographs were obtained at baseline and 1, 2, and 3 years. The main outcome measure was progression to proliferative diabetic retinopathy or worsening of 2 or more severity levels on reading-center masked assessment of 7-field fundus photographs, plus additional eyes that received panretinal photocoagulation or had a vitreous hemorrhage. RESULTS: From July 15, 2004, through May 5, 2006, 840 eyes from 693 participants were enrolled in the study and randomly assigned to receive laser therapy (n = 330), 1 mg of triamcinolone acetonide (n = 256), or 4 mg of triamcinolone acetonide (n = 254). The cumulative probability of progression of retinopathy at 2 years was 31% ( laser group), 29% (1-mg group), and 21% (4-mg group) (P = .64 in the 1-mg group and .005 in the 4-mg group compared with the laser group). These differences appeared to be sustained at 3 years. CONCLUSIONS:
|
Authors | Neil M Bressler, Allison R Edwards, Roy W Beck, Christina J Flaxel, Adam R Glassman, Michael S Ip, Craig Kollman, Baruch D Kuppermann, Thomas W Stone, Diabetic Retinopathy Clinical Research Network |
Journal | Archives of ophthalmology (Chicago, Ill. : 1960)
(Arch Ophthalmol)
Vol. 127
Issue 12
Pg. 1566-71
(Dec 2009)
ISSN: 1538-3601 [Electronic] United States |
PMID | 20008708
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
|
Chemical References |
- Glucocorticoids
- Triamcinolone Acetonide
|
Topics |
- Diabetic Retinopathy
(drug therapy, physiopathology, surgery, therapy)
- Disease Progression
- Female
- Follow-Up Studies
- Glucocorticoids
(administration & dosage)
- Humans
- Injections
- Laser Coagulation
(methods)
- Macular Edema
(drug therapy, physiopathology, surgery, therapy)
- Male
- Middle Aged
- Probability
- Triamcinolone Acetonide
(administration & dosage)
- Visual Acuity
(physiology)
- Vitreous Body
|